Abstract: The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity an

Abstract: The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity an

Abstract: The present invention relates to an aqueous coating material comprising at least one ionically and/or nonionically stabilized polyurethane, which is saturated, unsaturated and/or grafted with olefinically unsaturated compounds, and at least one organic, aliphatic solvent, wherein said solvent has a solubility parameter ?<10 (cal/cm3)1/2 and a degree of branching corresponding to a ratio of the number of CH and CH2 groups to the number of CH3 groups of at least 25:75. The invention further relates to a process for preparing it and to its use.

Abstract: The present invention relates to aqueous basecoat materials which comprise high-functionality, highly branched or hyperbranched polycarbonates based on dialkyl or diaryl carbonates or on phosgene, diphosgene or triphosgene and on aliphatic, aliphatic/aromatic or aromatic diols or polyols.

Abstract: A structural element for thermal insulation between two structural elements to be covered with concrete, especially a building and a projecting external part, has an insulating body to be inserted in between the structual elements and has at least integral compression elements which run transverse to the longitudinal extension of the insulating body and through them and are respectively connected to both structural elements, wherein the compression elements can have of a profile body with several especially vertically running compression bars, and wherein the length of the compression elements in the direction of the longitudinal extension of the insulating body amounts to a multiple of their vertical height.